Webinar: TDI 132 Information
March 12, 2012
This February, the ALS Therapy Development Institute announced that it plans to launch a clinical trial on a potential treatment for ALS called TDI 132 (aka fingolimod or Gilenya®). The March webinar will focus on this effort. We will provide an overview of the scientific rationale for this exciting planned trial as well as discuss the next steps forward. Drs. Steve Perrin (ALS TDI) and James Berry (MGH/HMS) will be panelists for this discussion.
Advanced registration is required. View the archived webinar here.